Drug details

Livtencity (maribavir tablets)

type of Antivirals, CMV

Livtencity (maribavir) is a cytomegalovirus (CMV) pUL97 kinase inhibitor indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. 

This drug may have the following side effects:

• severe dizziness
• swelling of your face, lips, tongue, or throat, and
• hives, 
• difficulty breathing, 

The following drugs are related to Livtencity, either as a replacement or used together:

• Cytogam (cytomegalovirus immune globulin intravenous human)
• Cytovene (ganciclovir)
• Prevymis (letermovir tablets)
• Valtrex (valacyclovir hydrochloride)
• Valcyte (valganciclovir hcl)